At present, the global pharmaceutical market is surging, and it has become very common
for multinational pharmaceutical companies to extend or expand product lines, cut costs, and optimize organizational structures through layoffs, investments, acquisitions, etc.
On September 27, local time, Biohaven said that the previously announced Pfizer acquisition of Biohaven is expected to be completed
on October 3, 2022.
Meanwhile, Biohaven's medical business on amyotrophic lateral sclerosis and obsessive-compulsive disorder was spun off into the new Biohaven, which is also expected to be completed
on October 3.
It is understood that Biohaven is a commercialization stage biopharmaceutical company that has developed several product pipelines in the late stages of clinical development based on a platform of multiple different mechanisms, with indications for migraine, obsessive-compulsive disorder, epilepsy, spinal cerebellar ataxia (SCA), amyotrophic lateral sclerosis ("Frostbite", ALS) and so on
.
Migraine is a chronic disease of repeated mild or severe headaches, according to statistics, the total number of migraine patients worldwide exceeds 1 billion people, mainly in young and middle-aged people, and the incidence of women is higher than that of men
.
The NURTECODT (Rimegepant) developed by Biohaven is the first calcitonin gene-related peptide (CGRP) receptor antagonist of oral disintegration tablets (ODT) preparations, which is a novel rapidly dissolving oral tablet dosage form that blocks CGRP receptors by reversibility, thereby inhibiting the biological activity
of CGRP neuropeptides.
The drug was first approved in February 2020 for the acute treatment of migraine (with or without aura) in adults, and in May 2021 it was approved for a new indication for the preventive treatment
of migraine.
According to the data, NURTECODT (Rimegepant) has sold a cumulative sales of $526 million from the official commercial launch in March 2020 to December 31, 2021, with a total of 1.
6 million prescriptions (commercial insurance coverage is about 90%)
.
On May 10, Pfizer announced its proposed acquisition of Biohaven for $11.
6 billion, at a premium of 78.
6%.
Upon completion of the acquisition, in addition to NURTECODT (Rimegepant), Pfizer will acquire the Phase 3 migraine candidate zavegepant and other late-stage assets
for the treatment of conditions such as obsessive-compulsive disorder, amyotrophic lateral sclerosis and spinal muscular atrophy.
Since the beginning of this year, in the pharmaceutical industry, multinational pharmaceutical companies are actively promoting mergers and acquisitions projects, and market changes have accelerated
.
In addition to Pfizer's acquisition of Biohaven, GlaxoSmithKline, AstraZeneca, Merck and so on also have mergers and acquisitions
.
For example, in July, Merck and Orion announced that they have reached a global R&D cooperation agreement to jointly develop Orion's investigational therapy ODM-208 and other drugs targeting cytochrome P450 11A1 (CYP11A1), of which ODM-208 is a CYP11A1-specific oral non-steroid inhibitor discovered and developed by Orion for the treatment of hormone-dependent cancers, such as prostate cancer
.
Currently, it is being used in Phase 2 clinical trials to treat metastatic castration-resistant prostate cancer
.
Globally, prostate cancer is the second most common cancer in men, with an estimated 1.
4 million people diagnosed
in 2020.
About 10 to 20% of advanced prostate cancers will turn into castration-resistant prostate cancer (CRPC)
within 5 years.
Also in July, AstraZeneca said it would acquire TeneoTwo for up to $1.
27 billion to strengthen its blood disease cancer product line
.
The transaction is expected to close
in the third quarter of 2022.
Under the terms of the agreement, AstraZeneca will receive all equity stakes in TeneoTwo, paying an advance payment of $100 million upon completion of the transaction; In addition, AstraZeneca will pay TeneoTwo's shareholders an additional R&D-related milestone of up to US$801 million and a commercial-related milestone of
up to US$360 million.
Following this acquisition, AstraZeneca will further enrich the company's hematology pipeline
.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"Share to:","viewSize:"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)];
